Literature DB >> 20538043

Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation.

E Norsted Gregory1, S Codeluppi, J A Gregory, J Steinauer, C I Svensson.   

Abstract

mTOR, the mammalian target of rapamycin, is a serine-threonine kinase known to regulate cell proliferation and growth. mTOR has also been implicated in neuronal synaptic plasticity as well as in pain transmission in models of chemically induced and neuropathic pain. To date, the role of mTOR as a modulator of inflammatory pain has not been examined. In this study, we investigated the role of mTOR in Sprague-Dawley rats using the carrageenan model of inflammatory pain. mRNA of Ras homolog enriched in brain (Rheb), a GTPase that positively regulates mTOR activation, was significantly increased 2 h following carrageenan injection. Four hours after induction of inflammation phosphorylation (p) of p70S6 kinase (S6K), ribosomal protein S6 (S6) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) was increased, indicating mTOR activation. Inhibition of spinal mTOR with intrathecal (i.t.) injection of rapamycin (0.1-3 microg) led to a dose-dependent decrease in carrageenan-induced thermal hyperalgesia and a reduction of mechanical allodynia. In vitro studies confirmed rapamycin inhibition of the mTOR pathway. Carrageenan-induced activation of the mTOR pathway in rats was localized predominantly to dorsal horn neurons in the superficial lamina. Taken together, these data show that the mTOR pathway is activated in dorsal horn neurons during inflammatory pain, and that inhibition of spinal mTOR attenuates inflammation-induced thermal and tactile hypersensitivity. Hence, our study indicates that spinal mTOR is an important regulator of spinal sensitization and suggests that targeting mTOR may provide a new avenue for pain therapy. Copyright (c) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538043      PMCID: PMC2914192          DOI: 10.1016/j.neuroscience.2010.05.067

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  53 in total

1.  Bench to bedside: the development of rapamycin and its application to stent restenosis.

Authors:  S O Marx; A R Marks
Journal:  Circulation       Date:  2001-08-21       Impact factor: 29.690

Review 2.  Glia: a novel drug discovery target for clinical pain.

Authors:  Linda R Watkins; Steven F Maier
Journal:  Nat Rev Drug Discov       Date:  2003-12       Impact factor: 84.694

3.  A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus.

Authors:  Shao Jun Tang; Gerald Reis; Hyejin Kang; Anne-Claude Gingras; Nahum Sonenberg; Erin M Schuman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

Review 4.  eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation.

Authors:  A C Gingras; B Raught; N Sonenberg
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

5.  Brain-derived neurotrophic factor enhances neuronal translation by activating multiple initiation processes: comparison with the effects of insulin.

Authors:  N Takei; M Kawamura; K Hara; K Yonezawa; H Nawa
Journal:  J Biol Chem       Date:  2001-09-10       Impact factor: 5.157

6.  Spinal brain-derived neurotrophic factor (BDNF) produces hyperalgesia in normal mice while antisense directed against either BDNF or trkB, prevent inflammation-induced hyperalgesia.

Authors:  Rachel Groth; Lin Aanonsen
Journal:  Pain       Date:  2002-11       Impact factor: 6.961

7.  Upregulation of proinflammatory cytokines and nerve growth factor by intraplantar injection of capsaicin in rats.

Authors:  N E Saadé; C A Massaad; C I Ochoa-Chaar; S J Jabbur; B Safieh-Garabedian; S F Atweh
Journal:  J Physiol       Date:  2002-11-15       Impact factor: 5.182

Review 8.  The molecular dynamics of pain control.

Authors:  S P Hunt; P W Mantyh
Journal:  Nat Rev Neurosci       Date:  2001-02       Impact factor: 34.870

9.  Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase.

Authors:  Gary G Chiang; Robert T Abraham
Journal:  J Biol Chem       Date:  2005-05-16       Impact factor: 5.157

10.  The effects of protein phosphatase inhibitors on nociceptive behavioral responses of rats following intradermal injection of capsaicin.

Authors:  Xuan Zhang; Jing Wu; Li Fang; William D Willis
Journal:  Pain       Date:  2003-12       Impact factor: 6.961

View more
  42 in total

Review 1.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 2.  AMPK: An emerging target for modification of injury-induced pain plasticity.

Authors:  Theodore J Price; Gregory Dussor
Journal:  Neurosci Lett       Date:  2013-07-03       Impact factor: 3.046

3.  Sinomenine attenuates chronic inflammatory pain in mice.

Authors:  Shuo Li; Jing Han; Dong-Sheng Wang; Qi Yang; Bin Feng; Wen-Bo Kang; Le Yang; Gang Liu; Ming-Gao Zhao
Journal:  Metab Brain Dis       Date:  2016-09-01       Impact factor: 3.584

4.  Spinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats.

Authors:  Ming-Hung Shih; Sheng-Chin Kao; Wei Wang; Myron Yaster; Yuan-Xiang Tao
Journal:  J Pain       Date:  2012-02-15       Impact factor: 5.820

Review 5.  Targeting AMPK for the Alleviation of Pathological Pain.

Authors:  Marina N Asiedu; Gregory Dussor; Theodore J Price
Journal:  Exp Suppl       Date:  2016

6.  BDNF Activates mTOR to Upregulate NR2B Expression in the Rostral Anterior Cingulate Cortex Required for Inflammatory Pain-Related Aversion in Rats.

Authors:  Yuangui Zhang; Fanceng Ji; Gongming Wang; Dong He; Le Yang; Mengyuan Zhang
Journal:  Neurochem Res       Date:  2018-01-20       Impact factor: 3.996

7.  Rapamycin ameliorates neuropathic pain by activating autophagy and inhibiting interleukin-1β in the rat spinal cord.

Authors:  Tao Feng; Qin Yin; Ze-Lin Weng; Jian-Cheng Zhang; Kun-Feng Wang; Shi-Ying Yuan; Wei Cheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

8.  mTOR and its downstream pathway are activated in the dorsal root ganglion and spinal cord after peripheral inflammation, but not after nerve injury.

Authors:  Lingli Liang; Bo Tao; Longchang Fan; Myron Yaster; Yi Zhang; Yuan-Xiang Tao
Journal:  Brain Res       Date:  2013-04-11       Impact factor: 3.252

9.  mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK.

Authors:  Ohannes K Melemedjian; Arkady Khoutorsky; Robert E Sorge; Jin Yan; Marina N Asiedu; Arely Valdez; Sourav Ghosh; Gregory Dussor; Jeffrey S Mogil; Nahum Sonenberg; Theodore J Price
Journal:  Pain       Date:  2013-03-15       Impact factor: 6.961

10.  Mechanisms and pharmacology of neuropathic pain in multiple sclerosis.

Authors:  T Iannitti; B J Kerr; B K Taylor
Journal:  Curr Top Behav Neurosci       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.